TELIX PHARMACEUTICALS LTD(TLX.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

TLX.AU TELIX PHARMACEUTICALS LTD

Market Closed 05-17 16:12:00 AEST

14.80

-0.65

-4.21%

High15.23	Low14.80	Vol720.02K
Open15.22	D1 Closing15.45	Amplitude2.78%
Mkt Cap4.89B	Tradable Cap3.84B	Total Shares330.46M
T/O10.79M	T/O Rate0.28%	Tradable Shares259.51M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"TLX.AU","market":"AU","secType":"STK","nameCN":"TELIX PHARMACEUTICALS LTD","latestPrice":14.8,"timestamp":1715926320000,"preClose":15.45,"halted":0,"volume":720019,"delay":0,"nameEN":"TELIX PHARMACEUTICALS LTD","floatShares":259513795,"shares":330455778,"eps":0.0161,"marketStatus":"Market Closed","change":-0.65,"latestTime":"05-17 16:12:00 AEST","open":15.22,"high":15.23,"low":14.8,"amount":10785404,"amplitude":0.027832,"askPrice":14.81,"askSize":826,"bidPrice":14.8,"bidSize":2139,"shortable":3,"etf":0,"ttmEps":0.0161,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1716163200000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":15.45,"openAndCloseTimeList":[[1715904000000,1715925600000]],"volumeRatio":1.1739281989989407,"lotSize":1,"tradeCurrency":"AUD"},"requestUrl":"/m/hq/s/TLX.AU/wiki","defaultTab":"wiki","newsList":[{"id":"2436599634","title":"BRIEF-Telix Pharmaceuticals Says QTRLY Revenue Of A$175.0M, Up 75% On Q1 2023","url":"https://stock-news.laohu8.com/highlight/detail?id=2436599634","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2436599634?lang=en_us&edition=fundamental","pubTime":"2024-05-17 17:25","pubTimestamp":1715937912,"startTime":"0","endTime":"0","summary":"May 17 (Reuters) - Telix Pharmaceuticals Ltd   :   * QTRLY REVENUE OF A$175.0M, UP 75% ON Q1 2023   * Q1 OPERATING PROFIT OF A$28.5M, UP FROM A$5.6M OPERATING LOSS IN PRIOR CORRESPONDING QUARTER Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2435803538","title":"Inherited a substantial sum of money? Here's how I'd spend it (including the ASX stocks I'd buy)","url":"https://stock-news.laohu8.com/highlight/detail?id=2435803538","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2435803538?lang=en_us&edition=fundamental","pubTime":"2024-05-14 09:03","pubTimestamp":1715648597,"startTime":"0","endTime":"0","summary":"Given the topic, let's try to keep this article as light-hearted as possible. Let's assume that one day, out of the blue, you get a call from a lawyer telling you that your mysterious great aunt Holga recently passed away at the ripe old age of 106. You can only remember meeting Holga once – on a family trip to Dusseldorf when you were still a toddler – but you must have made a good impression, because she decided to leave you all her worldly possessions, including a significant sum of money.Sure, you feel sad for poor old Holga, but she had a good run. And so, before long, your thoughts turn to how you should spend this sum of money. It could set you up for the future – and might even allow you to retire early!But you've never had so much money before, and it's hard to work out where to start. Should you invest it all in stocks?Should you blow it all at the casino?In this article, we take a look at some of the most prudent ways you can use your surprise cash injection. After all, it's","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/05/14/inherited-a-substantial-sum-of-money-heres-how-id-spend-it-including-the-asx-stocks-id-buy/","is_publish_highlight":false,"gpt_icon":0},{"id":"2432803221","title":"Two high-flying ASX shares: One upgraded, one downgraded","url":"https://stock-news.laohu8.com/highlight/detail?id=2432803221","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2432803221?lang=en_us&edition=fundamental","pubTime":"2024-05-04 02:40","pubTimestamp":1714761600,"startTime":"0","endTime":"0","summary":"Two ASX shares that have made their shareholders smile this year are DroneShield Ltd  and Telix Pharmaceuticals Ltd . Since the start of the year, their shares have risen by approximately 120% and 50%, respectively. As a comparison, the Australian share market is up around 0.5% over the same period. However, one leading broker believes that one of these high-flying ASX shares could have peaked for the time being. This has led to its analysts downgrading its shares to a hold rating. The good news for the other share is that its analysts have gone the other way with it. Despite its very strong gains, the broker has upgraded it to a buy rating from hold this week. Which ASX shares has been downgraded?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/05/04/two-high-flying-asx-shares-one-upgraded-one-downgraded/","is_publish_highlight":false,"gpt_icon":0},{"id":"2432695404","title":"This fundie invested in Neuren at a $70m valuation. It's now $2.4 billion.","url":"https://stock-news.laohu8.com/highlight/detail?id=2432695404","media":"LiveWire","top":-1,"share":"https://ttm.financial/m/news/2432695404?lang=en_us&edition=fundamental","pubTime":"2024-05-02 09:00","pubTimestamp":1714611605,"startTime":"0","endTime":"0","summary":"The newly minted KP Rx Healthcare Opportunities Fund, managed by Hashan De Silva, comes from a strong pedigree.De Silva previously worked for Karst Peak, a spinoff from Tiger Management, run by legendary hedge fund manager Julian Robertson.Karst Peak founder Adam Leitzes is providing seed capital for KP Rx, following the playbook of Robertson, who seeded and mentored numerous ex-employees to run their own investment houses - affectionately known as \"Tiger cubs\".In addition to the seed capital from Karst Peak, KP Rx’s investors include some of Australia’s most successful healthcare entrepreneurs including Dr Chris Behrenbruch , Patrick Davies , Lou Panaccio  to name a few.The fund is not focused on GP clinics, hospitals, or healthcare services. Rather, it focuses on later-stage businesses, with De Silva describing KP Rx as a \"series A, B, or C investor, where we are coming in once a lot of the initial preclinical stuff has been done.\". Previous successful investments include now ASX-lis","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/this-fundie-invested-in-neuren-at-a-70m-valuation-it-s-now-2-4-billion","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/this-fundie-invested-in-neuren-at-a-70m-valuation-it-s-now-2-4-billion","is_publish_highlight":false,"gpt_icon":0},{"id":"2429643015","title":"Analysis of Telix Pharmaceuticals, Bank of Queensland, MAAS Group Holdings","url":"https://stock-news.laohu8.com/highlight/detail?id=2429643015","media":"Informed Investor","top":-1,"share":"https://ttm.financial/m/news/2429643015?lang=en_us&edition=fundamental","pubTime":"2024-04-24 14:23","pubTimestamp":1713939783,"startTime":"0","endTime":"0","summary":"Fund Manager Chris Pedersen discusses Telix Pharmaceuticals, Bank of Queensland and MAAS Group Holdings.","market":null,"thumbnail":"https://informed-investor.s3.ap-southeast-2.amazonaws.com/images/News/59eae21f0fdaf33d285b41d0ffa8d2675fc2646e.jpg","type":0,"news_type":0,"thumbnails":["https://informed-investor.s3.ap-southeast-2.amazonaws.com/images/News/59eae21f0fdaf33d285b41d0ffa8d2675fc2646e.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.sharecafe.com.au/2024/04/24/analysis-of-telix-pharmaceuticals-bank-of-queensland-maas-group-holdings/","is_publish_highlight":false,"gpt_icon":0},{"id":"2429104434","title":"Up 74% in 6 months, guess which ASX 200 healthcare stock just hit another all-time high","url":"https://stock-news.laohu8.com/highlight/detail?id=2429104434","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2429104434?lang=en_us&edition=fundamental","pubTime":"2024-04-24 14:07","pubTimestamp":1713938856,"startTime":"0","endTime":"0","summary":"One ASX healthcare stock is clocking a new record price today while the S&P/ASX 200 Index  struggles to keep its head above water.The Aussie share market is flailing this afternoon after the Australian Bureau of Statistics  published March inflation figures.To the absolute displeasure of Australian equity investors, the monthly consumer price index rose 1.0% in the March-ending quarter, reflecting an annual rate of 3.6%. Economists were expecting 3.5%. The concern of a prolonged interest rate pause is dampening much of the market today.But breaking through the bemoaning bout is an ASX healthcare stock on a roll. Factoring in today's 4% gain, this little beauty is up 73.9% in a six-month timespan.I'm talking about none other than Telix Pharmaceuticals Ltd .Why are investors buying up this ASX healthcare stock?Topping it off, the ASX healthcare stock reaffirmed guidance of US$445 million to US$465 million in revenue for FY2024.Monash Investors' Shane Fitzgerald has described this ASX hea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/04/24/up-74-in-6-months-guess-which-asx-200-healthcare-stock-just-hit-another-all-time-high/","is_publish_highlight":false,"gpt_icon":0},{"id":"2429155171","title":"Why we believe Telix Pharmaceuticals is an attractive investment","url":"https://stock-news.laohu8.com/highlight/detail?id=2429155171","media":"LiveWire","top":-1,"share":"https://ttm.financial/m/news/2429155171?lang=en_us&edition=fundamental","pubTime":"2024-04-23 14:18","pubTimestamp":1713853110,"startTime":"0","endTime":"0","summary":"In the dynamic landscape of investing, uncovering hidden gems amidst the sea of opportunities often requires a keen eye for potential change and growth catalysts. Telix Pharmaceuticals , despite its relatively short tenure on the ASX, emerges as a beacon of promise in the realm of biotech ventures.In evaluating investment opportunities, the lack of an extensive historical record can obscure a company’s growth inflection points, which are critical to our decision-making process. In their absence, we rely on historical analogs from our investment experience to identify key performance indicators. Telix Pharmaceuticals, despite its brief history on the ASX, has demonstrated extraordinary progress by generating over $100 million in revenue in the March 2023 quarter, a remarkable leap from zero, less than twelve months ago. The rapid growth underscores the significant potential of their product offerings.Anticipated growth hinges on Telix’s entry into the radio-diagnostic markets for kidney","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/why-we-believe-telix-pharmaceuticals-is-an-attractive-investment","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/why-we-believe-telix-pharmaceuticals-is-an-attractive-investment","is_publish_highlight":false,"gpt_icon":0},{"id":"2429952474","title":"The Australian small-cap that could become the next CSL","url":"https://stock-news.laohu8.com/highlight/detail?id=2429952474","media":"LiveWire","top":-1,"share":"https://ttm.financial/m/news/2429952474?lang=en_us&edition=fundamental","pubTime":"2024-04-22 07:00","pubTimestamp":1713740405,"startTime":"0","endTime":"0","summary":"A little over six months ago, Monash Investors’ Shane Fitzgerald tipped small caps to outperform in 2024, after a lacklustre period. Since then, the ASX Small Ordinaries index has pulled ahead of the ASX 200, as high valuations in larger companies have driven a rotation by investors.The Small Ords is up 15% since October, versus 11% for the ASX 200. In Australia at least, this coincides with the national conversation shifting toward the first interest rate cuts as opposed to further hiking from the central bank.“Investors’ willingness to go down the risk curve is heightened because now that inflation is tamed, the large caps go back to being their boring old selves,” says Fitzgerald, co-founder and director of Monash Investors.“Now, we're in an environment where quality growth will do well – and you can find a lot more quality growth in the small-cap space than in large caps,” he says.In the following, Fitzgerald explains why and discusses how his team finds opportunities. He also expl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/the-australian-small-cap-that-could-become-the-next-csl","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/the-australian-small-cap-that-could-become-the-next-csl","is_publish_highlight":false,"gpt_icon":0},{"id":"2428530906","title":"Here are the top 10 ASX 200 shares today","url":"https://stock-news.laohu8.com/highlight/detail?id=2428530906","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2428530906?lang=en_us&edition=fundamental","pubTime":"2024-04-18 15:00","pubTimestamp":1713423622,"startTime":"0","endTime":"0","summary":"It turned out to be a day of high relief for ASX investors, with the S&P/ASX 200 Index  finally recording a positive session after five days of falls in a row.By the close of trade, the ASX 200 had gained a decent 0.48%, which leaves the index at 7,642.1 points.This strong Thursday session for the Australian stock market comes after a contrastingly negative night up on the American markets overnight.The Dow Jones Industrial Average Index  ended up closing in the red after initially rising, notching a 0.12% loss.The Nasdaq Composite Index  fared far worse though, tanking by 1.15%.But let's return to more positive things, with a look at what the various ASX sectors were up to today.But losers we still had. The most prominent of which were healthcare shares. The S&P/ASX 200 Healthcare Index  missed out on the good mood today, slumping 0.47%.Communications stocks were also left behind. The S&P/ASX 200 Communication Services Index  ended up losing 0.25%.Consumer discretionary stocks were ma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/04/18/here-are-the-top-10-asx-200-shares-today-394/","is_publish_highlight":false,"gpt_icon":0},{"id":"2428580434","title":"Why BHP, Challenger, Rio Tinto, and Telix shares are pushing higher today","url":"https://stock-news.laohu8.com/highlight/detail?id=2428580434","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2428580434?lang=en_us&edition=fundamental","pubTime":"2024-04-18 11:47","pubTimestamp":1713412031,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index (ASX: XJO) is back on form and pushing higher on Thursday. In afternoon trade, the benchmark index is up 0.6% to 7,650.2 points. Four ASX shares that are rising more than most tod","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/04/18/why-bhp-challenger-rio-tinto-and-telix-shares-are-pushing-higher-today/","is_publish_highlight":false,"gpt_icon":0},{"id":"2428301053","title":"BUZZ-Australia's Telix Pharmaceuticals hits record high on strong quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2428301053","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2428301053?lang=en_us&edition=fundamental","pubTime":"2024-04-18 08:36","pubTimestamp":1713400574,"startTime":"0","endTime":"0","summary":"** Shares of Telix Pharmaceuticals    jump as much as 15.3% to A$13.25 to hit a record high    ** Stock emerges as top gainer on the benchmark index    ** The biopharma co reports an 18% rise in quarterly revenue on prior quarter too $114.9 mln, driven by sales of its prostate cancer imaging product Illuccix   ** Co reaffirms FY revenue between $445 mln to $465 mln    ** Shares poised to see their best day since July 21, 2022 - if current trend holds    ** Stock has risen 24.4% this year as of last close ","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428308667","title":"ASX 200 to open higher, S&P 500 and Nasdaq fall for a fourth straight day","url":"https://stock-news.laohu8.com/highlight/detail?id=2428308667","media":"LiveWire","top":-1,"share":"https://ttm.financial/m/news/2428308667?lang=en_us&edition=fundamental","pubTime":"2024-04-18 06:51","pubTimestamp":1713394265,"startTime":"0","endTime":"0","summary":"ASX 200 futures are trading 20 points higher, up 0.26% as of 8:30 am AEST.S&P 500 sold off intraday to finish near session lows . S&P 500 finished lower, ending near worst levels despite a positive open. S&P 500 now down 3.4% in the last four sessions and marks the first four-session decline since the start of 2024. Bond yields lower across the curve after a sharp two-day run-up. Oil prices fell ~3% as a rise in US commercial inventories, weaker economic data from China and hawkish Fedspeak outweighed Middle East supply risks. Risk-off narrative continues to focus on the hawkish repricing of Fed rate-cut expectations, geopolitical fears of a wider Middle East war, unwinding of stretched positioning and sentiment indicators. South Korea policymakers increase warnings over rapidly weakening won . ASX 200 set to open higher on Thursday after a five-day losing streak. Netanyahu pushes back against Western calls for restraint and says Israel will do \"everything necessary\" to defend itself .","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/asx-200-to-open-higher-s-p-500-and-nasdaq-fall-for-a-fourth-straight-day","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/asx-200-to-open-higher-s-p-500-and-nasdaq-fall-for-a-fourth-straight-day","is_publish_highlight":false,"gpt_icon":0},{"id":"2428679343","title":"BRIEF-Telix Pharmaceuticals Posts Q1 Unaudited Total Revenue Of $114 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2428679343","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2428679343?lang=en_us&edition=fundamental","pubTime":"2024-04-17 15:41","pubTimestamp":1713339685,"startTime":"0","endTime":"0","summary":"April 17 (Reuters) - Telix Pharmaceuticals Ltd   :   * Q1 UNAUDITED TOTAL REVENUE OF US$114 MILLION, UP 18% QOQ   * REAFFIRMS GUIDANCE FOR FULL YEAR REVENUE EXPECTED TO BE IN RANGE OF $445M TO $465MFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428614333","title":"Press Release: Q1 2024 Revenue and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2428614333","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2428614333?lang=en_us&edition=fundamental","pubTime":"2024-04-17 15:05","pubTimestamp":1713337500,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia, April 17, 2024  -- Telix Pharmaceuticals Limited  today provides an update on its revenue and operational performance for the quarter ended 31 March 2024 .The Company reports unaudited total revenue of US$114.9M , an increase of 18% on the prior quarter . Revenue was primarily generated from sales of Telix's prostate cancer imaging product Illuccix.U.S. revenue grew by 18% to US$111.8M , compared to 11% growth between Q3 2023 and Q4 2023.Dr Christian Behrenbruch, Managing Director and Group CEO of Telix, commented, \"The continued, consistent growth of our precision diagnostics business is further evidence of an effective market growth strategy for our prostate cancer franchise. The dual benefit of an early revenue stream, and the ability to fund our late-stage therapeutic programs ensures we are on track to achieve major milestones in 2024 including the progression of three drug approval submissions in the U.S. and the international expansion of our Phase III Pros","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2427827388","title":"QSAM ANNOUNCES REVERSE STOCK SPLIT RATIO AHEAD OF MERGER","url":"https://stock-news.laohu8.com/highlight/detail?id=2427827388","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2427827388?lang=en_us&edition=fundamental","pubTime":"2024-04-16 20:30","pubTimestamp":1713270600,"startTime":"0","endTime":"0","summary":"Austin, TX, April 16, 2024  -- QSAM Biosciences, Inc.   previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of QSAM’s common stock, par value $0.0001 per share , at a ratio in the range of 1:1000 to 1:2000, prior to the closing of the merger between the Company and Telix Pharmaceuticals Limited   pursuant to which Telix will acquire QSAM .On April 15, 2024, the Board of Directors of QSAM unanimously approved that the reverse stock split ratio be 1-for-2,000 such that once the reverse stock split goes into effect, every holder of Common Stock of the Company shall receive one share of Common Stock for every 2,000 shares of Common Stock held . On February 7, 2024, a majority of the voting shareholders of QSAM approved the reverse stock split and granted the Board the discretion to adopt the ratio prior to the closing of the Merger, which ratio the Board has adopted and is announcing today.Forward-Looking Statements: This release contains","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/MjbGsB.uW8zfA8wZQggK4Q--~B/aD0xMDA7dz0yNjQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/00d51fabd4bcd044ccd1544d875406e9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/MjbGsB.uW8zfA8wZQggK4Q--~B/aD0xMDA7dz0yNjQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/00d51fabd4bcd044ccd1544d875406e9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/qsam-announces-reverse-stock-split-123000802.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2427814716","title":"Market Close: ASX launches liferafts in a sea of red and wounded","url":"https://stock-news.laohu8.com/highlight/detail?id=2427814716","media":"The Market Herald","top":-1,"share":"https://ttm.financial/m/news/2427814716?lang=en_us&edition=fundamental","pubTime":"2024-04-16 16:01","pubTimestamp":1713254460,"startTime":"0","endTime":"0","summary":"After shedding nearly double what futures had predicted, the ASX200 closed the day 1.8 per cent down. At one stage the ASX was on track for its worst day in 13 months and at the close, real estate, consumer stocks and mining were all licking their wounds.All sectors finished in a sea of red with the big four banks, ANZ, CBA, NAB and Westpac, all losing around 2 percent.Both Coles Group Limited.  Share Price | Latest News – The Market Online and Woolworths Group Limited  Share Price | Latest News – The Market Onlinefinished the day down around 1 and a half per cent amidst heated hearings involving the two supermarkets giants in Canberra.Electrical, communication and other services provider Southern Cross Electrical Engineering Ltd  Share Price | Latest News – The Market Online was up nearly 6 per cent after securing contract extensions at two data centres in New South Wales as well as a range of building projects in the ACT for a total of $50 million.And cancer immunotherapy company Imu","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://themarketonline.com.au/market-close-asx-launches-liferafts-in-a-sea-of-red-and-wounded-2024-04-16/","is_publish_highlight":false,"gpt_icon":0},{"id":"2427076893","title":"Market Update: ASX slides deeper on a slippier than expected slope","url":"https://stock-news.laohu8.com/highlight/detail?id=2427076893","media":"The Market Herald","top":-1,"share":"https://ttm.financial/m/news/2427076893?lang=en_us&edition=fundamental","pubTime":"2024-04-16 12:17","pubTimestamp":1713241020,"startTime":"0","endTime":"0","summary":"The ASX200 has shed nearly double what futures predicted, trading down 2.05%. All 11 sectors are in the red. Discretionary has lost the most so far, down 2.6%. Real Estate follows, down 2.305%, while in Canberra supermarket executives saw red under the duress of a parliamentary probe.Both Coles Coles Group Limited.  Share Price | Latest News – The Market Online and Woolworths Group Limited  Share Price | Latest News – The Market Online shares are down around 1 and a half per cent amidst heated hearings involving the two supermarkets giants. At one stage tempers got so frayed that former Woolworths CEO Brad Banducci was threatened with contempt – and potential jail time – if he continued to avoid answering questions as he crossed swords with forthright Greens Senator Nick McKim.The CEOs of both companies are facing a Senate inquiry as the government continues to investigate allegations of price gouging.China has reported economic growth of 5.3% in the first quarter, surpassing economist","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://themarketonline.com.au/market-update-asx-slides-deeper-on-a-slippier-than-expected-slope-2024-04-16/","is_publish_highlight":false,"gpt_icon":0},{"id":"2427893519","title":"Why Decmil, SCEE, Spartan Resources, and Telix shares are pushing higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2427893519","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2427893519?lang=en_us&edition=fundamental","pubTime":"2024-04-16 11:50","pubTimestamp":1713239458,"startTime":"0","endTime":"0","summary":"The S&P/ASX 200 Index (ASX: XJO) is having a day to forget on Tuesday. In afternoon trade, the benchmark index is down a very disappointing 2.1% to 7,586.6 points. Four ASX shares that are avoiding th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/04/16/why-decmil-scee-spartan-resources-and-telix-shares-are-pushing-higher/","is_publish_highlight":false,"gpt_icon":0},{"id":"2427861498","title":"Telix Pharmaceuticals granted US-FDA fast track designation for brain cancer detection","url":"https://stock-news.laohu8.com/highlight/detail?id=2427861498","media":"The Market Herald","top":-1,"share":"https://ttm.financial/m/news/2427861498?lang=en_us&edition=fundamental","pubTime":"2024-04-16 10:42","pubTimestamp":1713235320,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  has been granted Fast Track designation by The United States Food and Drug Administration  for its brain cancer imaging software; TLX101-CDx .This Fast Track designation is specifically for using TLX101-CDx with positron emission tomography  to characterize progressive or recurrent glioma, a form of brain cancer.Telix is currently in the final stages of preparing its U.S. New Drug Application  for TLX101-CDx in this initial indication, in both adult and paediatric patients. This designation enables expedited review and closer consultation with the FDA during the review process.While amino acid PET imaging is recommended in U.S. and European guidelines for glioma imaging, there is currently no FDA-approved targeted PET agent for brain cancer imaging in the U.S. Telix aims to change that by making TLX101-CDx commercially available in the U.S., which could significantly improve patient access to this important imaging tool – which the market currently lacks.Furtherm","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://themarketonline.com.au/telix-pharmaceuticals-granted-us-fda-fast-track-designation-for-brain-cancer-detection-2024-04-16/","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://telixpharma.com","stockEarnings":[{"period":"1week","weight":-0.0445},{"period":"1month","weight":0.1802},{"period":"3month","weight":0.3442},{"period":"6month","weight":0.5761},{"period":"1year","weight":0.3005},{"period":"ytd","weight":0.4683}],"compareEarnings":[{"period":"1week","weight":0.0049},{"period":"1month","weight":0.0587},{"period":"3month","weight":0.0966},{"period":"6month","weight":0.1366},{"period":"1year","weight":0.1436},{"period":"ytd","weight":0.1212}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"Telix Pharmaceuticals Limited, an oncology company, develops molecularly targeted radiation products for unmet needs in cancer care in Australia. Its lead products include TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in pre-Phase 3 development for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX591-CDx that is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; and TLX101, which is in Phase I/II clinical trial for the treatment of glioblastoma (brain cancer). The company has a development collaboration agreement with ARTMS Products Inc. for the manufacture of its prostate cancer imaging product TLX591-CDx (68Ga-PSMA-11 injection) for the imaging of prostate cancer with Positron Emission Tomography (PET). Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.142857,"avgChangeRate":-0.055106},{"month":2,"riseRate":0.571429,"avgChangeRate":-0.00178},{"month":3,"riseRate":0.857143,"avgChangeRate":0.161224},{"month":4,"riseRate":0.714286,"avgChangeRate":0.094005},{"month":5,"riseRate":0.333333,"avgChangeRate":0.060282},{"month":6,"riseRate":0.666667,"avgChangeRate":0.111666},{"month":7,"riseRate":0.5,"avgChangeRate":0.104857},{"month":8,"riseRate":0.5,"avgChangeRate":-0.036531},{"month":9,"riseRate":0.666667,"avgChangeRate":0.05206},{"month":10,"riseRate":0.833333,"avgChangeRate":0.211878},{"month":11,"riseRate":0.285714,"avgChangeRate":0.007547},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.00088}],"exchange":"ASX","name":"TELIX PHARMACEUTICALS LTD","nameEN":"TELIX PHARMACEUTICALS LTD"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"TELIX PHARMACEUTICALS LTD(TLX.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest TELIX PHARMACEUTICALS LTD(TLX.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"TELIX PHARMACEUTICALS LTD,TLX.AU,TELIX PHARMACEUTICALS LTD股票,TELIX PHARMACEUTICALS LTD股票老虎,TELIX PHARMACEUTICALS LTD股票老虎国际,TELIX PHARMACEUTICALS LTD行情,TELIX PHARMACEUTICALS LTD股票行情,TELIX PHARMACEUTICALS LTD股价,TELIX PHARMACEUTICALS LTD股市,TELIX PHARMACEUTICALS LTD股票价格,TELIX PHARMACEUTICALS LTD股票交易,TELIX PHARMACEUTICALS LTD股票购买,TELIX PHARMACEUTICALS LTD股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"TELIX PHARMACEUTICALS LTD(TLX.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest TELIX PHARMACEUTICALS LTD(TLX.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction